BidaskClub lowered shares of NuVasive (NASDAQ:NUVA) from a strong-buy rating to a buy rating in a research report sent to investors on Friday.

A number of other equities research analysts have also commented on NUVA. Royal Bank of Canada upped their price target on NuVasive to $70.00 and gave the company an outperform rating in a research report on Tuesday, November 27th. Robert W. Baird upgraded NuVasive from a neutral rating to an outperform rating and increased their price target for the stock from $60.00 to $82.00 in a report on Thursday, September 27th. ValuEngine lowered NuVasive from a buy rating to a hold rating in a report on Thursday, November 1st. Cantor Fitzgerald reiterated a hold rating and issued a $58.00 price target on shares of NuVasive in a report on Friday, October 19th. Finally, Morgan Stanley increased their price target on NuVasive from $55.00 to $77.00 and gave the stock a hold rating in a report on Tuesday, September 25th. Three research analysts have rated the stock with a sell rating, eight have given a hold rating and nine have assigned a buy rating to the stock. The company currently has a consensus rating of Hold and a consensus price target of $66.82.

NUVA traded down $1.74 during trading on Friday, hitting $56.12. The stock had a trading volume of 602,516 shares, compared to its average volume of 490,708. The company has a market capitalization of $2.98 billion, a PE ratio of 29.38, a price-to-earnings-growth ratio of 1.73 and a beta of 0.80. NuVasive has a one year low of $44.62 and a one year high of $72.41. The company has a debt-to-equity ratio of 0.74, a current ratio of 3.45 and a quick ratio of 1.83.

NuVasive (NASDAQ:NUVA) last released its earnings results on Tuesday, October 30th. The medical device company reported $0.56 earnings per share for the quarter, missing analysts’ consensus estimates of $0.62 by ($0.06). NuVasive had a net margin of 2.24% and a return on equity of 13.87%. The company had revenue of $271.30 million for the quarter, compared to the consensus estimate of $265.70 million. During the same quarter in the previous year, the company posted $0.52 earnings per share. The business’s revenue was up 9.7% compared to the same quarter last year. Equities analysts anticipate that NuVasive will post 2.18 earnings per share for the current fiscal year.

In other news, insider Matthew Link sold 1,200 shares of the stock in a transaction that occurred on Friday, November 16th. The stock was sold at an average price of $62.01, for a total value of $74,412.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Over the last three months, insiders sold 8,671 shares of company stock valued at $538,741. Company insiders own 1.20% of the company’s stock.

Several institutional investors have recently modified their holdings of NUVA. Tower Research Capital LLC TRC increased its position in shares of NuVasive by 163.8% during the third quarter. Tower Research Capital LLC TRC now owns 2,469 shares of the medical device company’s stock valued at $175,000 after acquiring an additional 1,533 shares during the last quarter. Honkamp Krueger Financial Services Inc. purchased a new stake in shares of NuVasive during the third quarter valued at approximately $183,000. GSA Capital Partners LLP purchased a new stake in shares of NuVasive during the third quarter valued at approximately $209,000. Zions Bancorporation purchased a new stake in shares of NuVasive during the third quarter valued at approximately $225,000. Finally, Strs Ohio increased its position in shares of NuVasive by 45.5% during the second quarter. Strs Ohio now owns 3,200 shares of the medical device company’s stock valued at $166,000 after acquiring an additional 1,000 shares during the last quarter.

NuVasive Company Profile

NuVasive, Inc, a medical device company, develops and markets minimally-disruptive surgical products and procedurally-integrated solutions for spine surgery. Its products focus on applications for spine fusion surgery, including ancillary products and services used to aid in the surgical procedure. The company's principal product is Maximum Access Surgery, a minimally-disruptive surgical platform, which includes its software-driven nerve detection and avoidance systems, and intraoperative monitoring (IOM) services and support; MaXcess, an integrated split-blade retractor system; and various specialized implants and biologics.

Featured Article: How to interpret a stock’s beta number

Analyst Recommendations for NuVasive (NASDAQ:NUVA)

Receive News & Ratings for NuVasive Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NuVasive and related companies with MarketBeat.com's FREE daily email newsletter.